We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00035022
Recruitment Status : Completed
First Posted : May 3, 2002
Last Update Posted : January 13, 2006
Information provided by:
BioCryst Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : No date given
  Estimated Study Completion Date : March 2004